Targeting cell cycle regulation in cancer therapy.

Abstract:

:Cell proliferation is an essential mechanism for growth, development and regeneration of eukaryotic organisms; however, it is also the cause of one of the most devastating diseases of our era: cancer. Given the relevance of the processes in which cell proliferation is involved, its regulation is of paramount importance for multicellular organisms. Cell division is orchestrated by a complex network of interactions between proteins, metabolism and microenvironment including several signaling pathways and mechanisms of control aiming to enable cell proliferation only in response to specific stimuli and under adequate conditions. Three main players have been identified in the coordinated variation of the many molecules that play a role in cell cycle: i) The cell cycle protein machinery including cyclin-dependent kinases (CDK)-cyclin complexes and related kinases, ii) The metabolic enzymes and related metabolites and iii) The reactive-oxygen species (ROS) and cellular redox status. The role of these key players and the interaction between oscillatory and non-oscillatory species have proved essential for driving the cell cycle. Moreover, cancer development has been associated to defects in all of them. Here, we provide an overview on the role of CDK-cyclin complexes, metabolic adaptations and oxidative stress in regulating progression through each cell cycle phase and transitions between them. Thus, new approaches for the design of innovative cancer therapies targeting crosstalk between cell cycle simultaneous events are proposed.

journal_name

Pharmacol Ther

authors

Diaz-Moralli S,Tarrado-Castellarnau M,Miranda A,Cascante M

doi

10.1016/j.pharmthera.2013.01.011

subject

Has Abstract

pub_date

2013-05-01 00:00:00

pages

255-71

issue

2

eissn

0163-7258

issn

1879-016X

pii

S0163-7258(13)00023-5

journal_volume

138

pub_type

杂志文章,评审
  • Novel therapeutic agents for lowering low density lipoprotein cholesterol.

    abstract::Elevated low density lipoprotein cholesterol (LDL-C) levels have been associated with an increased risk for cardiovascular disease (CVD). Despite a 25-30% reduction in CVD risk with LDL-C reducing strategies, there is still a significant residual risk. Moreover, achieving target LDL-C values in individuals at high CVD...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2012.03.005

    authors: Joy TR

    更新日期:2012-07-01 00:00:00

  • Vascular Disrupting Agents in cancer treatment: Cardiovascular toxicity and implications for co-administration with other cancer chemotherapeutics.

    abstract::Destruction of the established tumour vasculature by a class of compound termed Vascular Disrupting Agents (VDAs) is showing considerable promise as a viable approach for the management of solid tumours. VDAs induce a rapid shutdown and collapse of tumour blood vessels, leading to ischaemia and consequent necrosis of ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2019.06.001

    authors: Gill JH,Rockley KL,De Santis C,Mohamed AK

    更新日期:2019-10-01 00:00:00

  • TSPO in diverse CNS pathologies and psychiatric disease: A critical review and a way forward.

    abstract::The use of Translocator Protein 18 kDa (TSPO) as a clinical neuroimaging biomarker of brain injury and neuroinflammation has increased exponentially in the last decade. There has been a furious pace in the development of new radiotracers for TSPO positron emission tomography (PET) imaging and its use has now been exte...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2018.09.003

    authors: Guilarte TR

    更新日期:2019-02-01 00:00:00

  • K(+) channels as therapeutic drug targets.

    abstract::K(+) channels play critical roles in a wide variety of physiological processes, including the regulation of heart rate, muscle contraction, neurotransmitter release, neuronal excitability, insulin secretion, epithelial electrolyte transport, cell volume regulation, and cell proliferation. As such, K(+) channels have b...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/s0163-7258(02)00201-2

    authors: Wickenden A

    更新日期:2002-04-01 00:00:00

  • Estradiol effects on hypothalamic AMPK and BAT thermogenesis: A gateway for obesity treatment?

    abstract::In addition to their prominent roles in the control of reproduction, estrogens are important modulators of energy balance, as evident in conditions of deficiency of estrogens, which are characterized by increased feeding and decreased energy expenditure, leading to obesity. AMP-activated protein kinase (AMPK) is a ubi...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2017.03.014

    authors: López M,Tena-Sempere M

    更新日期:2017-10-01 00:00:00

  • Current investigations on clinical pharmacology and therapeutics of Glucose-6-phosphate dehydrogenase deficiency.

    abstract::Glucose-6-phospate dehydrogenase (G6PD) deficiency is estimated to affect more than 400 million people world-wide. This X-linked genetic deficiency puts stress on red blood cells (RBC), which may be further augmented under certain pathophysiological conditions and drug treatments. These conditions can cause hemolytic ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107788

    authors: Ryan K,Tekwani BL

    更新日期:2020-12-14 00:00:00

  • Binge-eating disorder: Clinical and therapeutic advances.

    abstract::Binge-eating disorder (BED) is the most prevalent eating disorder with estimates of 2-5% of the general adult population. Nonetheless, its pathophysiology is poorly understood. Furthermore, there exist few therapeutic options for its effective treatment. Here we review the current state of binge-eating neurobiology an...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2017.08.002

    authors: Hutson PH,Balodis IM,Potenza MN

    更新日期:2018-02-01 00:00:00

  • Allosteric pathways in nuclear receptors - Potential targets for drug design.

    abstract::The nuclear receptor family of transcription factor proteins mediates endocrine function and plays critical roles in the development, physiology and pharmacology. Malfunctioning nuclear receptors are associated with several disease states. The functional activity of nuclear receptors is regulated by small molecular ho...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2017.10.014

    authors: Fernandez EJ

    更新日期:2018-03-01 00:00:00

  • Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): Clinical candidate for cancer therapy.

    abstract::Chemoresistance, radioresistance, and the challenge of achieving complete resection are major driving forces in the search for more robust and targeted anticancer therapies. Targeting the DNA damage response has recently attracted research interest, as these processes are enhanced in tumour cells. The major replicatio...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107518

    authors: Gorecki L,Andrs M,Rezacova M,Korabecny J

    更新日期:2020-06-01 00:00:00

  • "Disease modifying nutricals" for multiple sclerosis.

    abstract::The association between vitamin D and multiple sclerosis has (re)-opened new interest in nutrition and natural compounds in the prevention and treatment of this neuroinflammatory disease. The dietary amount and type of fat, probiotics and biologicals, salmon proteoglycans, phytoestrogens and protease inhibitor of soy,...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2014.11.015

    authors: Schmitz K,Barthelmes J,Stolz L,Beyer S,Diehl O,Tegeder I

    更新日期:2015-04-01 00:00:00

  • Emerging pharmacologic targets and treatments for myocarditis.

    abstract::Myocarditis is a heterogeneous group of disorders defined by inflammation of the heart muscle. The primary clinical manifestations of myocarditis are heart failure and sudden death in children and young adults. Numerous interventions have been investigated for the treatment of myocarditis, including broad spectrum alt...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2016.03.006

    authors: Jensen LD,Marchant DJ

    更新日期:2016-05-01 00:00:00

  • Role of Ca(2+) and vitamin D in the prevention and treatment of osteoporosis.

    abstract::Osteoporosis is defined as a progressive systemic skeletal disease characterised by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture. The clinical relevance of osteoporosis derives from the fractures that it produces. More th...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/s0163-7258(02)00164-x

    authors: Rodríguez-Martínez MA,García-Cohen EC

    更新日期:2002-01-01 00:00:00

  • Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia.

    abstract::In mediating the transfer of cholesteryl esters (CE) from antiatherogenic high density lipoprotein (HDL) to proatherogenic apolipoprotein (apo)-B-containing lipoprotein particles (including very low density lipoprotein [VLDL], VLDL remnants, intermediate density lipoprotein [IDL], and low density lipoprotein [LDL]), t...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2003.10.001

    authors: Le Goff W,Guerin M,Chapman MJ

    更新日期:2004-01-01 00:00:00

  • Targeting PI3 kinase in cancer.

    abstract::The PI3K/Akt/mTOR pathway is the most frequently known activated aberrant pathway in human cancers. Pathologic activation can occur at multiple levels along the signaling pathway by a variety of mechanisms, including point mutations, amplifications, and inactivation of tumor suppressor genes. This pathway is also a kn...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2014.09.006

    authors: Bauer TM,Patel MR,Infante JR

    更新日期:2015-02-01 00:00:00

  • Structure-function relationships of acid ribonucleases: lysosomal, vacuolar, and periplasmic enzymes.

    abstract::It is surprising that only relatively recently has attention been directed to the characterization of the properties of acid ribonucleases (RNases), leading to some understanding of their biochemistry and their functional roles. The present review summarizes current progress in this field under the following general t...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/s0163-7258(98)00035-7

    authors: Irie M

    更新日期:1999-02-01 00:00:00

  • Overcoming drug resistance to receptor tyrosine kinase inhibitors: Learning from lung cancer.

    abstract::There are various receptor tyrosine kinase (TK)-targeted drugs that are currently used in the treatment of patients with non-small cell lung cancer (NSCLC). Among them, the epidermal growth factor receptor (EGFR) TK inhibitors (TKIs) are the most extensively studied. Receptor TKIs including EGFR TKIs have shown dramat...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2016.03.002

    authors: Kuwano M,Sonoda K,Murakami Y,Watari K,Ono M

    更新日期:2016-05-01 00:00:00

  • Leukocyte integrins: role in leukocyte recruitment and as therapeutic targets in inflammatory disease.

    abstract::Infection or sterile inflammation triggers site-specific attraction of leukocytes. Leukocyte recruitment is a process comprising several steps orchestrated by adhesion molecules, chemokines, cytokines and endogenous regulatory molecules. Distinct adhesive interactions between endothelial cells and leukocytes and signa...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2014.11.008

    authors: Mitroulis I,Alexaki VI,Kourtzelis I,Ziogas A,Hajishengallis G,Chavakis T

    更新日期:2015-03-01 00:00:00

  • Cyclic nucleotide phosphodiesterases: pharmacology, biochemistry and function.

    abstract::This article is a review of cyclic nucleotide phosphodiesterase(s) (CN PDE) from the point of view of the relationships between the newer aspects of the complex enzymology of CN PDE and recent major advances in CN PDE pharmacology. A consolidation of isozyme nomenclature to the proposed family designations is recommen...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/0163-7258(91)90039-o

    authors: Thompson WJ

    更新日期:1991-01-01 00:00:00

  • Gender disparity in cardiac electrophysiology: implications for cardiac safety pharmacology.

    abstract:BACKGROUND:Gender differences in cardiac electrophysiology were reported for the first time almost a century ago. The importance for safety pharmacology became significant when modern medicine came into use and women appeared to be more susceptible to drug-induced Torsade de Pointes (TdP). To unravel the underlying mec...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2010.04.002

    authors: Jonsson MK,Vos MA,Duker G,Demolombe S,van Veen TA

    更新日期:2010-07-01 00:00:00

  • Primaquine pharmacology in the context of CYP 2D6 pharmacogenomics: Current state of the art.

    abstract::Primaquine is the only antimalarial drug available to clinicians for the treatment of relapsing forms of malaria. Primaquine development and usage dates back to the 1940s and has been administered to millions of individuals to treat and eliminate malaria infections. Primaquine therapy is not without disadvantages, how...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2016.03.011

    authors: Marcsisin SR,Reichard G,Pybus BS

    更新日期:2016-05-01 00:00:00

  • Biological effects of inhibitors of S-adenosylhomocysteine hydrolase.

    abstract::S-Adenosylhomocysteine (AdoHcy), formed after the donation of the methyl group of S-adenosylmethionine to a methyl acceptor, is hydrolyzed to adenosine and homocysteine by AdoHcy hydrolase physiologically. The administration of the inhibitors of AdoHcy hydrolase to cells or animals normally results in an accumulation ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/s0163-7258(97)00089-2

    authors: Chiang PK

    更新日期:1998-02-01 00:00:00

  • Endothelial dysfunction in cirrhosis and portal hypertension.

    abstract::Portal hypertension (PHT) is a common clinical syndrome associated with chronic liver diseases; it is characterized by a pathological increase in portal pressure. Pharmacotherapy for PHT is aimed at reducing both intrahepatic vascular tone and elevated splanchnic blood flow. Due to the altered hemodynamic profile in P...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/s0163-7258(01)00128-0

    authors: Cahill PA,Redmond EM,Sitzmann JV

    更新日期:2001-03-01 00:00:00

  • Coronary microcirculation: physiology and pharmacology.

    abstract::Coronary microvessels play a pivotal role in determining the supply of oxygen and nutrients to the myocardium by regulating the coronary flow conductance and substance transport. Direct approaches analyzing the coronary microvessels have provided a large body of knowledge concerning the physiological and pharmacologic...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/s0163-7258(00)00057-7

    authors: Komaru T,Kanatsuka H,Shirato K

    更新日期:2000-06-01 00:00:00

  • New drugs vs. old concepts: a fresh look at antiarrhythmics.

    abstract::Common arrhythmias, particularly atrial fibrillation (AF) and ventricular tachycardia/fibrillation (VT/VF) are a major public health concern. Classic antiarrhythmic (AA) drugs for AF are of limited effectiveness, and pose the risk of life-threatening VT/VF. For VT/VF, implantable cardiac defibrillators appear to be th...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2011.03.003

    authors: Thireau J,Pasquié JL,Martel E,Le Guennec JY,Richard S

    更新日期:2011-11-01 00:00:00

  • Acquisition of inhibitor-sensitive protein kinases through protein design.

    abstract::Protein phosphorylation is the major post-translational modification used by eukaryotic cells to control cellular signaling. Protein kinases have emerged as attractive drug targets because heightened protein kinase activity has been associated with several proliferative diseases, most notably cancer and restenosis. Un...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/s0163-7258(98)00060-6

    authors: Bishop AC,Shokat KM

    更新日期:1999-05-01 00:00:00

  • KRAS-related proteins in pancreatic cancer.

    abstract::Pancreatic ductal adenocarcinoma (PDAC) is a highly metastatic disease with a high mortality rate. Genetic and biochemical studies have shown that RAS signaling mediated by KRAS plays a pivotal role in disease initiation, progression and drug resistance. RAS signaling affects several cellular processes in PDAC, includ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2016.09.003

    authors: Mann KM,Ying H,Juan J,Jenkins NA,Copeland NG

    更新日期:2016-12-01 00:00:00

  • G-protein-coupled receptor dimerization: modulation of receptor function.

    abstract::G-protein-coupled receptors (GPCRs) comprise the largest family of transmembrane receptors in the human genome that respond to a plethora of signals, including neurotransmitters, peptide hormones, and odorants, to name a few. They couple to second messenger signaling cascade mechanisms via heterotrimeric G-proteins. R...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/s0163-7258(01)00160-7

    authors: Rios CD,Jordan BA,Gomes I,Devi LA

    更新日期:2001-11-01 00:00:00

  • KIT as a therapeutic target for non-oncological diseases.

    abstract::KIT is a receptor tyrosine kinase that after binding to its ligand stem cell factor activates signaling cascades linked to biological processes such as proliferation, differentiation, migration and cell survival. Based on studies performed on SCF and/or KIT mutant animals that presented anemia, sterility, and/or pigme...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2018.12.008

    authors: Martinez-Anton A,Gras D,Bourdin A,Dubreuil P,Chanez P

    更新日期:2019-05-01 00:00:00

  • Nicotinic acetylcholine receptors: from basic science to therapeutics.

    abstract::Substantial progress in the identification of genes encoding for a large number of proteins responsible for various aspects of neurotransmitter release, postsynaptic detection and downstream signaling, has advanced our understanding of the mechanisms by which neurons communicate and interact. Nicotinic acetylcholine r...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2012.08.012

    authors: Hurst R,Rollema H,Bertrand D

    更新日期:2013-01-01 00:00:00

  • Exercise and endothelial function: role of endothelium-derived nitric oxide and oxidative stress in healthy subjects and hypertensive patients.

    abstract::Recent epidemiologic studies have shown that aerobic exercise, one of lifestyle modifications, reduces cardiovascular morbidity and mortality in the general population. However, the mechanisms underlying the anti-atherogenic and anti-hypertensive effects of exercise remain unclear. Hypertension is associated with alte...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2004.02.003

    authors: Higashi Y,Yoshizumi M

    更新日期:2004-04-01 00:00:00